These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 10738843)

  • 41. A multicenter, randomized controlled clinical study on biapenem and imipenem/cilastatin injection in the treatment of respiratory and urinary tract infections.
    Jia B; Lu P; Huang W; Li C; Huang A; Zhou X; Zhang W; Wu G; Zhang G
    Chemotherapy; 2010; 56(4):285-90. PubMed ID: 20714145
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem.
    Day IP; Goudie J; Nishiki K; Williams PD
    Toxicol Lett; 1995 Apr; 76(3):239-43. PubMed ID: 7762010
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts. Italian Intramuscular Meropenem Study Group.
    Romanelli G; Cravarezza P
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():109-19. PubMed ID: 8543487
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer).
    Biron P; Fuhrmann C; Cure H; Viens P; Lefebvre D; Thyss A; Viot M; Soler-Michel P; Rollin C; Grès JJ
    J Antimicrob Chemother; 1998 Oct; 42(4):511-8. PubMed ID: 9818751
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safe use of meropenem in a patient with a possible nonimmediate allergy to imipenem.
    Lakhal K; Lortat-Jacob B; Neukirch C; Pajot O; Wolff M
    Pharmacotherapy; 2007 Sep; 27(9):1334-8. PubMed ID: 17723087
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.
    Lee LS; Kinzig-Schippers M; Nafziger AN; Ma L; Sörgel F; Jones RN; Drusano GL; Bertino JS
    Diagn Microbiol Infect Dis; 2010 Nov; 68(3):251-8. PubMed ID: 20851549
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Carbapenems in pediatrics.
    Ayalew K; Nambiar S; Yasinskaya Y; Jantausch BA
    Ther Drug Monit; 2003 Oct; 25(5):593-9. PubMed ID: 14508383
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.
    Balfour JA; Bryson HM; Brogden RN
    Drugs; 1996 Jan; 51(1):99-136. PubMed ID: 8741235
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery.
    Kanellakopoulou K; Giamarellou H; Papadothomakos P; Tsipras H; Chloroyiannis J; Theakou R; Sfikakis P
    Eur J Clin Microbiol Infect Dis; 1993 Jun; 12(6):449-53. PubMed ID: 8359165
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Pharmacoeconomics of meropenem versus imipenem/cilastatin].
    Marquina MC; Giráldez J; Idoate A
    Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():45-50. PubMed ID: 9410069
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Meropenem: a review of its use in patients in intensive care.
    Hurst M; Lamb HM
    Drugs; 2000 Mar; 59(3):653-80. PubMed ID: 10776838
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Imipenem/cilastatin treatment of bacterial meningitis in children.
    Wong VK; Wright HT; Ross LA; Mason WH; Inderlied CB; Kim KS
    Pediatr Infect Dis J; 1991 Feb; 10(2):122-5. PubMed ID: 2062603
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin.
    Dreetz M; Hamacher J; Eller J; Borner K; Koeppe P; Schaberg T; Lode H
    Antimicrob Agents Chemother; 1996 Jan; 40(1):105-9. PubMed ID: 8787889
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Imipenem-cilastatin sodium, a broad-spectrum carbapenem antibiotic combination.
    Pastel DA
    Clin Pharm; 1986 Sep; 5(9):719-36. PubMed ID: 3530614
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Meropenem monotherapy is as effective as and safer than imipenem to treat brain abscesses.
    Martin-Canal G; Saavedra A; Asensi JM; Suarez-Zarracina T; Rodriguez-Guardado A; Bustillo E; Fierer J; Carton JA; Collazos J; Asensi V
    Int J Antimicrob Agents; 2010 Mar; 35(3):301-4. PubMed ID: 20045289
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New antibiotics.
    Friedland IR; Lutsar I
    Curr Opin Pediatr; 1998 Feb; 10(1):41-5. PubMed ID: 9529636
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lack of cross-reactivity to meropenem in a patient with an allergy to imipenem-cilastatin.
    Bauer SL; Wall GC; Skoglund KJ; Peters LK
    J Allergy Clin Immunol; 2004 Jan; 113(1):173-5. PubMed ID: 14713926
    [No Abstract]   [Full Text] [Related]  

  • 58. Risk/benefit in the treatment of children with imipenem-cilastatin for meningitis caused by penicillin-resistant pneumococcus.
    Asensi F; Otero MC; Pérez-Tamarit D; Rodríguez-Escribano I; Cabedo JL; Gresa S; Cantón E
    J Chemother; 1993 Apr; 5(2):133-4. PubMed ID: 8515296
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males.
    Nilsson-Ehle I; Hutchison M; Haworth SJ; Norrby SR
    Eur J Clin Microbiol Infect Dis; 1991 Feb; 10(2):85-8. PubMed ID: 1864280
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety of imipenem/cilastatin in neurocritical care patients.
    Hoffman J; Trimble J; Brophy GM
    Neurocrit Care; 2009; 10(3):403-7. PubMed ID: 19116700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.